"I think that, across industries, AI is going to provide a great benefit to our day-to-day practice," says Michael Karellas, MD.
In this video, Michael Karellas, MD, discusses the potential uses of artificial intelligence in urologic cancers. Karellas is an assistant professor of urology at Yale School of Medicine a member of Yale Cancer Center in New Haven, Connecticut.
In general, technology is improving our day-to-day practice overall. I think that, across industries, AI is going to provide a great benefit to our day-to-day practice. But in the oncology world, the way it's helping us primarily right now is in the data research and some of the algorithms behind the scenes. But in day-to-day practice, we're not quite there yet, as far as having AI dictate your cancer care. As an extension of that, most of the cancers that we treat have guidelines that are established by national bodies that are evidence based. From that aspect, we rely on AI heavily or just database management in general, but the way the guidelines are structured, and for most cancers, there's a nuanced approach and an individualized approach for patients with their cancer care. Our challenge over the years has been to try to integrate the data with the patient care, and I think AI will help us with that, but we're not quite there yet in a day-to-day practice modality.
This transcription was edited for clarity.